ERRATUM

Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

Fausto Roila¹ • David Warr² • Paul J. Hesketh³ • Richard Gralla⁴ • Jorn Herrstedt⁵ • Karin Jordan⁶ • Matti Aapro⁷ • Enzo Ballatori⁸ • Bernardo Rapoport⁹

Published online: 14 September 2016
© Springer-Verlag Berlin Heidelberg 2016

Erratum to: Support Care Cancer
DOI 10.1007/s00520-016-3365-1

Table 1 in the original article is unfortunately incorrect. The correct Table 1 is shown below and the original article was corrected.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00520-016-3365-1>.

✉ Fausto Roila
roila.fausto@libero.it

- ¹ Medical Oncology, Santa Maria Hospital, Via Tristano di Joannuccio 1, 05100 Terni, Italy
- ² Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Canada
- ³ Lahey Health Cancer Institute, Burlington, USA
- ⁴ Albert Einstein College of Medicine, Jacobi Medical Center, New York, NY, USA
- ⁵ Department of Oncology, Odense University, 5000 Odense, Denmark
- ⁶ Department of Hematology/Oncology, Martin Luther University, Halle-Wittenberg, Halle, Germany
- ⁷ Clinique de Genolier, Multidisciplinary Oncology Institute, Genolier, Switzerland
- ⁸ Spinetoli, Italy
- ⁹ Medical Oncology Centre of Rosebank, 129 Oxford Road, Johannesburg, South Africa

Table 1 Recommendations for moderately emetogenic chemotherapy

Chemotherapy	Recommendations		MASCC level of scientific confidence/level of consensus	ESMO level of evidence / grade of recommendation
	Old	New		
MEC				
Acute	Palo + Dex	5HT3 + Dex	Moderate / moderate	II / B
Delayed	Dex ^a	Dex ^a	Low / moderate	III / C
		None ^b	No confidence possible / high	IV / D
CARBOPLATIN				
Acute	Palo + Dex	NK1 + 5-HT3 + DEX	Moderate / moderate	II / B
Delayed	Dex ^a	Apre ^c	Moderate / moderate	II / B

MEC moderately emetogenic chemotherapy, *Palo* palonosetron, *Dex* dexamethasone, *Apre* aprepitant

^a only in patients with known potential for delayed emesis

^b the steroid can be considered only in patients receiving MEC with known potential for delayed emesis

^c only in patients receiving aprepitant 125 mg on day 1